Education
About Us
Working with TipRanks
Follow Us
aTyr Pharma (ATYR)
NASDAQ:ATYR
Top Page
aTyr Pharma
(NASDAQ:ATYR)
Select Model
Select Model
Rating:40Underperform
Price Target:
$1.00
▼(-4.76% Downside)
The overall stock score for aTyr Pharma is primarily impacted by its challenging financial performance, characterized by ongoing losses and negative cash flows. Technical analysis indicates bearish momentum, with the stock being oversold, which could suggest a potential for a short-term rebound. Valuation metrics are unfavorable due to negative earnings and lack of dividends.
Positive Factors
Strong Equity Position
A strong equity position provides aTyr Pharma with a solid financial foundation, allowing for greater resilience and flexibility in funding its R&D activities and potential future expansions.
Innovative Biopharmaceutical Platform
aTyr Pharma's proprietary platform targeting rare diseases and inflammatory conditions positions it well in the biotechnology sector, potentially leading to breakthroughs in unmet medical needs and long-term growth.
Clinical Improvement in Phase 3 Study
Despite not meeting the primary endpoint, the clinical improvement in lung function suggests potential for efzofitimod, supporting aTyr Pharma's commitment to addressing rare diseases and enhancing its market position.
Negative Factors
Ongoing Financial Losses
Persistent financial losses and negative cash flows can hinder aTyr Pharma's ability to invest in R&D and sustain operations, posing a risk to its long-term viability and growth prospects.
Phase 3 Study Primary Endpoint Not Met
Failure to meet the primary endpoint in a critical Phase 3 study may delay product approval and commercialization, impacting aTyr Pharma's revenue generation and strategic objectives.
Negative Revenue Growth
Declining revenue growth reflects challenges in product commercialization and market penetration, which could affect aTyr Pharma's ability to achieve sustainable profitability and long-term success.
aTyr Pharma (ATYR) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$100.44M
Dividend YieldN/A
Average Volume (3M)11.02M
Price to Earnings (P/E)―
Beta (1Y)1.32
Revenue Growth-100.00%
EPS Growth11.89%
CountryUS
Employees56
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.22
Shares Outstanding97,986,630
10 Day Avg. Volume25,024,735
30 Day Avg. Volume11,020,319
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap3.87
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-1.01K
Enterprise Value/Ebitda-5.62
Forecast
1Y Price Target
$6.92Price Target Upside559.05% Upside
Rating ConsensusHold
Number of Analyst Covering9
aTyr Pharma Business Overview & Revenue Model
Company DescriptionaTyr Pharma, Inc., a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. Its lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase III clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for treatment of other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD. The company is developing ATYR0101, a fusion protein derived from a domain of aspartyl-tRNA synthetase that is in preclinical development for the treatment of fibrosis; and ATYR0750, a domain of alanyl-tRNA synthetase for the treatment of liver disorders. It has collaboration and license agreement with Kyorin Pharmaceutical Co., Ltd. for the development and commercialization of efzofitimod for ILDs in Japan. aTyr Pharma, Inc. was incorporated in 2005 and is headquartered in San Diego, California.
How the Company Makes MoneyaTyr Pharma generates revenue primarily through the development and commercialization of its therapeutic candidates. The company may receive funding from government grants and research partnerships, as well as milestone payments from collaborations with pharmaceutical companies. Additionally, aTyr Pharma seeks to monetize its proprietary platform technology through licensing agreements with other biotech firms. The company is also focused on advancing its clinical trials to move products toward market approval, which can lead to revenue from product sales once therapies are commercialized.
aTyr Pharma Earnings Call Summary
Earnings Call Date:Aug 07, 2025
(Q4-2024)
| % Change Since: |
Next Earnings Date:Nov 06, 2025
Earnings Call Sentiment Positive
The earnings call highlighted significant progress in clinical trials and market opportunities, along with a solid financial position. However, there are challenges related to limited clinical studies for benchmarking and high unmet medical needs in the current market landscape.Q4-2024 Updates
Positive Updates
Completion of Enrollment in EFZO-FIT Phase 3 Study
aTyr completed enrollment in the global pivotal Phase 3 EFZO-FIT study of efzofitimod in patients with pulmonary sarcoidosis, enrolling 268 patients across 85 centers in 9 countries.
Positive Safety Profile in Phase 3 Study
Four positive data and safety monitoring board reviews for EFZO-FIT identified no safety concerns, recommending the study to continue unmodified.
Increased Market Opportunity for Efzofitimod
Recent analysis shows the U.S. patient population for sarcoidosis is 30% higher than previously estimated, suggesting a larger market opportunity for efzofitimod.
Publication in Science Translational Medicine
An extensive manuscript on efzofitimod's mechanism of action and preclinical data was published in the journal Science Translational Medicine, validating its immunomodulatory properties.
Strong Financial Position and Cash Runway
aTyr ended 2024 with $75.1 million in cash and raised an additional $18.8 million, with a cash runway expected to fund operations through one year following the Phase 3 EFZO-FIT readout.
Negative Updates
Limited Clinical Studies in Sarcoidosis
There are limited clinical studies in sarcoidosis to benchmark against, presenting challenges in pioneering a path forward for measuring improvements in this patient population.
Potential Market Challenges
Despite potential market opportunities, current treatment practices indicate significant mortality and hospitalization rates, reflecting high unmet medical needs.
Company Guidance
During aTyr Pharma's fourth quarter and full year 2024 conference call, the company provided comprehensive guidance on their clinical developments and strategic outlook. They highlighted the completion of enrollment in the pivotal Phase 3 EFZO-FIT study for efzofitimod, aimed at treating pulmonary sarcoidosis. This trial involves 268 patients across 85 centers in nine countries, testing doses of 3 mg/kg and 5 mg/kg against a placebo over 52 weeks, with a primary endpoint focused on steroid reduction. The company also noted that 75% of diagnosed sarcoidosis patients are prescribed steroids, with the U.S. patient population being 30% larger than previously estimated. Additionally, they have observed four positive data and safety monitoring board reviews with no safety concerns. Financially, aTyr ended 2024 with $75.1 million in cash, supplemented by $18.8 million from an ATM offering. They project their cash runway will last through a year following the Phase 3 readout. The company also discussed plans for commercial readiness and the potential for efzofitimod in a $2-5 billion ILD market, with sarcoidosis representing a significant portion.aTyr Pharma Financial Statement Overview
Summary
aTyr Pharma is experiencing substantial financial challenges, with a negative net profit margin and ongoing operational losses. Despite a strong equity position and manageable debt levels, declining revenue and negative cash flows significantly impact the financial outlook.Income Statement
aTyr Pharma's income statement shows significant challenges with sustained negative profitability. The gross profit margin was 100% in 2024 due to minimal revenue, but the company has a consistent negative net profit margin due to high expenses outweighing revenue, with a net income of -$64 million in 2024. Revenue growth was negative at -33.43% from 2023 to 2024, indicating a decline in sales. The EBIT and EBITDA margins are both negative, reflecting ongoing operational losses.35
Negative
Balance Sheet
The balance sheet shows a moderate financial position for aTyr Pharma. The debt-to-equity ratio is relatively low at 0.19, suggesting manageable leverage. However, the return on equity (ROE) is negative due to substantial net losses impacting shareholder value. The equity ratio stands at 72.33%, indicating a strong equity position relative to total assets.50
Neutral
Cash Flow
Cash flow analysis for aTyr Pharma reveals ongoing operational cash deficits, with an operating cash flow of -$69 million in 2024. The free cash flow growth rate is negative at -84.64%. The operating cash flow to net income ratio is slightly above 1, indicating operating losses are closely aligned with net income losses.40
Negative
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 235.00K | 353.00K | 10.39M | 0.00 | 10.46M |
| Gross Profit | -387.00K | 235.00K | 353.00K | 8.69M | -1.30M | -6.84M |
| EBITDA | -69.28M | -66.37M | -52.18M | -44.71M | -32.47M | -14.64M |
| Net Income | -66.64M | -64.02M | -50.39M | -45.34M | -33.77M | -16.22M |
Balance Sheet | ||||||
| Total Assets | 101.53M | 96.83M | 120.65M | 95.79M | 115.54M | 38.73M |
| Cash, Cash Equivalents and Short-Term Investments | 17.22M | 72.13M | 98.17M | 66.15M | 107.91M | 31.69M |
| Total Debt | 12.68M | 13.28M | 15.10M | 11.53M | 1.38M | 2.24M |
| Total Liabilities | 26.88M | 27.00M | 30.18M | 24.50M | 6.41M | 7.24M |
| Stockholders Equity | 74.84M | 70.02M | 90.66M | 71.46M | 109.30M | 31.65M |
Cash Flow | ||||||
| Free Cash Flow | -55.65M | -69.18M | -37.44M | -43.53M | -33.27M | -15.50M |
| Operating Cash Flow | -55.60M | -69.12M | -33.22M | -41.89M | -33.08M | -15.30M |
| Investing Cash Flow | 10.74M | 17.23M | -20.13M | 47.24M | -91.57M | 6.90M |
| Financing Cash Flow | 55.26M | 39.86M | 66.23M | 5.45M | 110.03M | 16.14M |
aTyr Pharma Technical Analysis
Negative
1.05
Price Trends
5.02
Negative
4.72
Negative
4.10
Negative
Market Momentum
-0.91
Positive
22.57
Positive
1.28
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ATYR, the sentiment is Negative. The current price of 1.05 is below the 20-day moving average (MA) of 4.52, below the 50-day MA of 5.02, and below the 200-day MA of 4.10, indicating a bearish trend. The MACD of -0.91 indicates Positive momentum. The RSI at 22.57 is Positive, neither overbought nor oversold. The STOCH value of 1.28 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ATYR.
aTyr Pharma Risk Analysis
aTyr Pharma disclosed 69 risk factors in its most recent earnings report. aTyr Pharma reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
aTyr Pharma Peers Comparison
Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
63 Neutral | 988.10M | -5.87 | -128.35% | ― | -0.90% | -89.51% | |
58 Neutral | 490.14M | -8.82 | -33.59% | ― | -26.88% | 13.41% | |
52 Neutral | 392.79M | 20.20 | 0.00% | ― | 2990.57% | 0.00% | |
46 Neutral | 531.92M | -4.43 | 0.00% | ― | 0.00% | 6.82% | |
43 Neutral | 378.93M | -3.20 | 0.00% | ― | 0.00% | -9.14% | |
40 Underperform | $100.44M | ― | -85.18% | ― | -100.00% | 11.89% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
Performance Comparison
ATYR
aTyr Pharma
1.05
-0.82
-43.85%
ARCT
Arcturus Therapeutics
19.62
-1.40
-6.66%
OLMA
Olema Pharmaceuticals
8.51
-5.09
-37.43%
ATAI
ATAI Life Sciences
4.72
3.46
274.60%
GLUE
Monte Rosa Therapeutics
6.93
0.68
10.88%
AURA
Aura Biosciences Inc
6.26
-3.43
-35.40%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.